GB202017058D0 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof

Info

Publication number
GB202017058D0
GB202017058D0 GBGB2017058.5A GB202017058A GB202017058D0 GB 202017058 D0 GB202017058 D0 GB 202017058D0 GB 202017058 A GB202017058 A GB 202017058A GB 202017058 D0 GB202017058 D0 GB 202017058D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2017058.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GBGB2017058.5A priority Critical patent/GB202017058D0/en
Publication of GB202017058D0 publication Critical patent/GB202017058D0/en
Priority to KR1020237017200A priority patent/KR20230113295A/ko
Priority to IL302244A priority patent/IL302244A/en
Priority to JP2023525485A priority patent/JP2023549067A/ja
Priority to US18/250,716 priority patent/US20250026813A1/en
Priority to CN202180085791.0A priority patent/CN117396501A/zh
Priority to PCT/EP2021/079901 priority patent/WO2022090353A1/en
Priority to MX2023004869A priority patent/MX2023004869A/es
Priority to CA3199594A priority patent/CA3199594A1/en
Priority to AU2021369450A priority patent/AU2021369450A1/en
Priority to EP21805859.2A priority patent/EP4237442A1/en
Priority to CONC2023/0006684A priority patent/CO2023006684A2/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
GBGB2017058.5A 2020-10-27 2020-10-27 Antibodies and uses thereof Ceased GB202017058D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2017058.5A GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof
EP21805859.2A EP4237442A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof
US18/250,716 US20250026813A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof
IL302244A IL302244A (en) 2020-10-27 2021-10-27 Antibodies against SARS-COV-2 and their uses
JP2023525485A JP2023549067A (ja) 2020-10-27 2021-10-27 Ｓａｒｓ－ｃｏｖ－２に対する抗体およびその使用
KR1020237017200A KR20230113295A (ko) 2020-10-27 2021-10-27 Sars-cov-2에 대한 항체 및 그의 용도
CN202180085791.0A CN117396501A (zh) 2020-10-27 2021-10-27 抗sars-cov-2抗体及其用途
PCT/EP2021/079901 WO2022090353A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof
MX2023004869A MX2023004869A (es) 2020-10-27 2021-10-27 Anticuerpos contra sars-cov-2 y usos de los mismos.
CA3199594A CA3199594A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof
AU2021369450A AU2021369450A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof
CONC2023/0006684A CO2023006684A2 (es) 2020-10-27 2023-05-23 Anticuerpos contra sars-cov-2 y usos de los mismos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2017058.5A GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof

Publications (1)

Publication Number Publication Date
GB202017058D0 true GB202017058D0 (en) 2020-12-09

Family

ID=73727037

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2017058.5A Ceased GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof

Country Status (12)

Country Link
US (1) US20250026813A1 (https=)
EP (1) EP4237442A1 (https=)
JP (1) JP2023549067A (https=)
KR (1) KR20230113295A (https=)
CN (1) CN117396501A (https=)
AU (1) AU2021369450A1 (https=)
CA (1) CA3199594A1 (https=)
CO (1) CO2023006684A2 (https=)
GB (1) GB202017058D0 (https=)
IL (1) IL302244A (https=)
MX (1) MX2023004869A (https=)
WO (1) WO2022090353A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114989255A (zh) * 2021-03-01 2022-09-02 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
CN114989263A (zh) * 2021-03-01 2022-09-02 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
US12496470B2 (en) 2021-07-14 2025-12-16 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
EP4630447A2 (en) * 2022-12-09 2025-10-15 Abwiz Bio, Inc. Antibodies or fragments thereof for sars-cov-2 and variants thereof
EP4649096A2 (en) * 2023-01-10 2025-11-19 Sana Biotechnology, Inc. Cd19-specific antibody constructs and compositions thereof
KR20250016745A (ko) * 2023-07-25 2025-02-04 연세대학교 산학협력단 신규한 펩타이드, 이를 포함하는 항체 또는 이의 항원 결합 단편, 이를 포함하는 SARS-CoV-2 검출용 물질

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114989255A (zh) * 2021-03-01 2022-09-02 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
CN114989263A (zh) * 2021-03-01 2022-09-02 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用
CN114989255B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
CN114989263B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用

Also Published As

Publication number Publication date
WO2022090353A1 (en) 2022-05-05
JP2023549067A (ja) 2023-11-22
KR20230113295A (ko) 2023-07-28
MX2023004869A (es) 2023-06-01
CO2023006684A2 (es) 2023-05-29
AU2021369450A1 (en) 2023-06-22
AU2021369450A9 (en) 2025-04-10
US20250026813A1 (en) 2025-01-23
IL302244A (en) 2023-06-01
CA3199594A1 (en) 2022-05-05
CN117396501A (zh) 2024-01-12
EP4237442A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
IL308808A (en) Antibodies against CCR8 and their uses
GB202017058D0 (en) Antibodies and uses thereof
IL276950A (en) Anti-CD73 antibodies and uses thereof
GB2610467B (en) Anti-CLL1 antibody and application thereof
IL307267A (en) ANTI-CD122 antibodies and their uses
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL310662A (en) Anti-CD161 antibodies and their uses
IL307940A (en) Anti-ADGRE2 antibodies and their uses
IL275826A (en) Anti-mct1 antibodies and their uses
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL319931A (en) Anti-CD122 antibodies and their uses
IL289656A (en) Anti-tigit antibodies and their application
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL308382A (en) New anti-CD276 antibodies and their uses
IL276548A (en) Binding antibodies - BCMA and their uses
SMT202600020T1 (it) Anticorpi monoclonali anti-gprc5d e usi di essi
IL307939A (en) Anti-CLEC12A antibodies and uses thereof
IL320586A (en) Anti-trem2 antibody and its uses
IL317391A (en) Novel anti-LILRB4 antibodies and their uses
IL304412A (en) Antibodies against cd112r and uses thereof
IL312584A (en) ANTI-VISTA antibodies and their uses
IL310810A (en) Anti-ACVR2A antibodies and uses thereof
EP4437000A4 (en) ANTI-TREM2 ANTIBODY AND ITS USES
EP4490199A4 (en) MODIFIED ANTIBODIES AND THEIR USES
IL319145A (en) Novel anti-LILRB2 antibodies and their uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)